en ENGLISH
eISSN: 2083-8441
ISSN: 2081-237X
Pediatric Endocrinology Diabetes and Metabolism
Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Suplementy Rada naukowa Recenzenci Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac Opłaty publikacyjne Standardy etyczne i procedury
Panel Redakcyjny
Zgłaszanie i recenzowanie prac online
SCImago Journal & Country Rank
4/2024
vol. 30
 
Poleć ten artykuł:
Udostępnij:
streszczenie artykułu:
Artykuł przeglądowy

Rola czynnika EP4 w cukrzycy typu 1 u dzieci – kompleksowy przegląd dotyczący okresu remisji choroby

Forough Taheri
1
,
Nekoo Panahi
1, 2
,
Aida Vahidi
1
,
Mojgan Asadi
1
,
Mahsa M. Amoli
1
,
Naieme Goharifar
3

  1. Metabolic Disorders Research Centre, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Iran
  2. Endocrinology and Metabolism Research Centre, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Iran
  3. Department of Biology, Faculty of Science and Technology, ACECR Institute of Higher Education, Isfahan, Iran
Pediatr Endocrinol Diabetes Metab 2024; 30 (4): 227-243
Data publikacji online: 2025/01/27
Pełna treść artykułu Pobierz cytowanie
 
Metryki PlumX:


The partial clinical recovery phase (PCRP), or “honeymoon period”, is a temporary and partial restoration of b-cell function in patients with type 1 diabetes mellitus (T1DM), in which the immune system attacks and destroys insulin-producing b-cells. The underlying causes of PCRP are not fully understood, but they are believed to involve a combination of genetic and environmental factors. Recent research has suggested a potential link between a specific allele of the prostaglandin receptor EP4 (PTGER4) and the modulation of remission in individuals with T1DM. This review aims to provide an overview of current scientific findings on the biological functions and role of the EP4 receptor in T1DM, with a particular focus on its involvement in the PCR phase. It provides a comprehensive understanding of the mechanisms underlying PCRP, which can lead to the development of more effective treatment strategies for preserving b-cell function and prolonging the PCRP. The identification of specific biomarkers associated with the PCRP and the EP4 receptor enables early identification of individuals at lower risk of long-term complications, facilitating targeted interventions and personalised treatment approaches.

© 2025 Termedia Sp. z o.o.
Developed by Bentus.